NetworkNewsBreaks – InMed Pharmaceuticals (CSE:
Post# of 228
(Total Views: 842)
Posted On: 09/01/2017 4:58:54 PM
NetworkNewsBreaks – InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Could Prove to Be a Cannabis Biotech Unicorn
The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼